Ocular adverse events due to PD-1 and PD-L1 checkpoint inhibitors: A retrospective review of FDA adverse events reporting system (FAERS)

被引：0
|
作者：
Sahu, Y. [1 ]
Ensor, J. [2 ]
Burns, E. [3 ]
Sahu, G. [4 ]
Iyer, S. P. [5 ]
Anand, K. [6 ]
机构：
[1] Safdarjang Hosp, Opthalmol, New Delhi, India
[2] Houston Methodist Res Inst, Oncol, Houston, TX USA
[3] Houston Methodist Hosp, Canc Ctr, Houston, TX 77030 USA
[4] Creighton Univ, Sch Med, Psychiat, North Platte, NE USA
[5] Univ Texas MD Anderson Canc Ctr, Lymphoma Myeloma, Houston, TX 77030 USA
[6] Great Plains Hlth, Canc Ctr, North Platte, NE USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
43P
引用
收藏
页码：S1433 / S1433
页数：1
相关论文
共 50 条
  • [21] Pulmonary Immune-Related Adverse Events ofPD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
    Ebinama, Ugochi
    Sheshadri, Ajay
    Anand, Kartik
    Swaminathan, Iyer
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (04) : 177 - 184
  • [22] Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
    Nigro, Olga
    Pinotti, Graziella
    De Galitiis, Federica
    Di Pietro, Francesca Romana
    Giusti, Raffaele
    Filetti, Marco
    Bersanelli, Melissa
    Lazzarin, Alessandro
    Bordi, Paola
    Catino, Annamaria
    Pizzutilo, Pamela
    Galetta, Domenico
    Marchetti, Paolo
    Botticelli, Andrea
    Scagnoli, Simone
    Russano, Marco
    Santini, Daniele
    Torniai, Mariangela
    Berardi, Rossana
    Ricciuti, Biagio
    De Giglio, Andrea
    Chiari, Rita
    Russo, Alessandro
    Adamo, Vincenzo
    Tudini, Marianna
    Silva, Rosa Rita
    Bolzacchini, Elena
    Giordano, Monica
    Di Marino, Pietro
    De Tursi, Michele
    Rijavec, Erika
    Ghidini, Michele
    Vallini, Ilaria
    Stucci, Luigia Stefania
    Tucci, Marco
    Pala, Laura
    Conforti, Fabio
    Queirolo, Paola
    Tanda, Enrica
    Spagnolo, Francesco
    Cecchi, Federica
    Bracarda, Sergio
    Macrini, Serena
    Santoni, Matteo
    Battelli, Nicola
    Fargnoli, Maria Concetta
    Porzio, Giampiero
    Tuzi, Alessandro
    Suter, Matteo Basilio
    Ficorella, Corrado
    EUROPEAN JOURNAL OF CANCER, 2020, 134 : 19 - 28
  • [23] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [24] PD-1/PD-L1 Inhibitor- Related Adverse Events and Their Management in Breast Cancer
    Lei, Chuqi
    Kong, Xiangyi
    Li, Yuan
    Yang, Huaiyu
    Zhang, Ke
    Wang, Zhongzhao
    Chang, Hu
    Xuan, Lixue
    JOURNAL OF CANCER, 2024, 15 (09): : 2770 - 2787
  • [25] Therapiemonitoring und Nebenwirkungsmanagement bei PD-1/PD-L1-Immuncheckpoint-InhibitionTherapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition
    H. Oppel-Heuchel
    M.-O. Grimm
    Der Urologe, 2016, 55 : 677 - 690
  • [26] CNS Radiation-Related Adverse Events in Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors
    Hubbeling, H.
    Schapira, E.
    Shaw, A.
    Oh, K. S.
    Gainor, J.
    Shih, H. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S150 - S151
  • [27] PD-1 immune checkpoint inhibitors and serious immune-related adverse events
    Baek, Yeon-Hee
    Kang, Eun Joo
    Hong, Soojung
    Park, So-Hee
    Kim, Ju Hwan
    Wong, Ian C.
    Au, Philip C. -M.
    Cheung, Ching-Lung
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 293 - 293
  • [28] Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
    Wang, Yucai
    Zhou, Shouhao
    Yang, Fang
    Qi, Xinyue
    Wang, Xin
    Guan, Xiaoxiang
    Shen, Chan
    Duma, Narjust
    Aguilera, Jesus Vera
    Chintakuntlawar, Ashish
    Price, Katharine A.
    Molina, Julian R.
    Pagliaro, Lance C.
    Halfdanarson, Thorvardur R.
    Grothey, Axel
    Markovic, Svetomir N.
    Nowakowski, Grzegorz S.
    Ansel, Stephen M.
    Wang, Michael L.
    JAMA ONCOLOGY, 2019, 5 (07) : 1008 - 1019
  • [29] Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
    Zhang, Yixi
    Wang, Jingyuan
    Hu, Taobo
    Wang, Huina
    Long, Mengping
    Liang, Baosheng
    LIFE-BASEL, 2022, 12 (12):
  • [30] Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance
    Bhardwaj, Maitry
    Chiu, Mei Nee
    Sah, Sangeeta Pilkhwal
    CUTANEOUS AND OCULAR TOXICOLOGY, 2022, 41 (01) : 73 - 90
12345